Successful treatment of refractory immune hemolysis following unrelated cord blood transplant with Campath-1H
Successful treatment of refractory immune hemolysis following unrelated cord blood transplant with Campath-1H
复制标题
DOI：
10.1002/pbc.21187
复制
发表时间：
2008-04-01
影响因子：
3.2
通讯作者：
Yanik, Gregory A.
中科院分区：
文献类型：
--
作者：
Chao, Mwe Mwe;Levine, John E.;Yanik, Gregory A.
免疫介导的溶血性贫血是造血干细胞移植的常见并发症。我们报告一个6岁的男孩与X-连锁肾上腺脑白质营养不良谁开发严重的迟发性同种免疫溶血性贫血与免疫介导的中性粒细胞减少症和血小板减少症后主要ABO血型不合无关的脐带血移植。患者的血细胞减少对皮质类固醇、环孢素、静脉注射免疫球蛋白、利妥昔单抗和喷司他丁治疗无效。在Campath-1H治疗一个疗程后，他的血液学参数恢复正常，表明该化合物可能是治疗造血干细胞移植并发的复杂免疫血液学疾病的有效方法。该病例还强调了T细胞在移植相关免疫性血细胞减少症中的重要性。
Immune-mediated hemolytic anemia is a well-recognized complication of hematopoietic stein cell transplantation. We report on a 6-year-old boy with X-linked adrenoleukodystrophy who developed severe delayed alloimmune hemolytic anemia associated with immune-mediated neutropenia and thrombocytopenia following major ABO incompatible unrelated cord blood transplantation. The patient's cytopenias were refractory to treatment with corticosteroids, cyclosporine, intravenous immune globulin, rituximab, and pentostatin. After one course of Campath-1H his hematologic parameters normalized, suggesting that the compound may be an effective therapy for complex immunohematologic disorders complicating hematopoietic stein cell transplantation. The case also emphasizes the importance of T-cells in transplant associated immune cytopenias.